why choose us

First received: October 12, 2022

Clinical Trial: Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Advanced Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Advanced Solid Tumors

Brief Summary: This study is a Phase 1b, single-center, open-label, dose-finding trial designed to identify the Recommended Phase 2 Dose (RP2D) of STI 6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with any advanced solid tumor.The patients that will be treated with STI-6129 in this trial are advanced solid tumor patients who have received prior lines of treatment.

Read more